YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Dermal Absorption and Body Distribution of $^{125}I-rhEGF$ in Hairless Mice

헤어리스마우스 피부 국소에 적용된 $^{125}I-rhEGF$의 피부흡수 및 체내 분포

  • Published : 1997.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Distribution of rhEGF in the skin, plasma and several organ tissues following topical application of $^{125}I-rhEGF$ (0.4${\mu}$Ci) solution in 25% Pluronic F-127 on 154$mm^2$ normal and damaged (burned and stripped) skins of hairless mice was examined. The radioactivity in the stripped skin tissues increased as a function of time, and was 10-20 times higher than that in the normal and burned skins. The fractions of intact drug in the skin tissues were 40-60% for the normal and burned skins, and 60-80% for the stripped skin. It indicates that the stratum corneum layer behaves as a barrier for the dermal penetration of the drug. The radioactivity in the plasma was much higher for the stripped skin than for the normal and burned skins. However, the concentration of intact drug in the stripped skin was comparable to those in the normal and burned skins indicating most severe degradation (or metabolism) of the drug in the stripped skin. As a result, the fraction of intact drug in the plasma was lowest for the stripped skin (<10%). Body organ distribution of the drug was much higher for the stripped skin. The concentration in the stomach. Both in total radioactivity and intact drug, showed more than 10-times higher value than in the other organs (liver, kidney and spleen). The fraction of intact drug in each organ tissue was below 10-20%. And generally lowest for the stripped skin. The lowest fraction of the drug for the stripped skin could not be explained by the activity of the aminopeptidases in the skin since it was lower for the stripped skin than for the normal skin. Thereover, the fraction of intact drug appears to be determined by the balance between dermal uptake and systemic elimination of the drug, for example. The mechanism of dermal uptake of rhEGF was examined by topical applying 200${\mu}$l of 25% Pluronic F-127 solution containing 0.4 ${\mu}$Ci of $^{125}I-rhEGF$ and 0.14${\mu}$Ci of $^{14}C$-inulin (a marker of passive diffusion). The radioactivity of $^{125}I-rhEGF$ at each sampling time point (0.5, 1, 2, 4 and 8hr) was correlated (p<0.05) with the corresponding radioactivity of $^{14}C$-inulin. It appears to indicate the rhEGF may be uptaken into the skins mainly by the passive diffusion. This hypothesis was supported by the constant specific binding of EGF to the skin homogenates regardless of the skin models. Receptor mediated endocytosis (RME) appears to contribute negligibly, if any, to the overall uptake process.

Keywords

References

  1. The Molecular and Cellular Biology of Wound Repair The role of growth factors in tissue repair Ⅱ. Banks, A. R.;Clark, R. A. F.(Ed.);Henson, P. M.(Ed.)
  2. Prog. Nucleic Acid Res. Mol. Biol. v.49 Interaction of epidermal growth factor with its receptor Campion, S. R.;Niyogi, S. K.
  3. Endocr. Rev. v.11 Metabolism and effects of epidermal growth factor and related grwoth factors in mammals Fisher, D. A.;Lakshmanan, J.
  4. J. Pharmacobio-Dyn. v.12 A sensitive enzyme immunoassay for human epidermal growth factor. Determination of hEGF in human serum and pharmacokinetics in mouse Hayashi, T.;Hashimoto, K.;Sakamoto, S.
  5. J. Cell Sci. v.S3 Epidermal growth factor. Biology and receptor metabolism Carpenter, G.
  6. Proc. Natl. Acad. Sci. USA v.82 Sustained release of EGF accelerates wound repair Buckley, A.;Davidson, J. M.;Kamerath, C. D.;Wolt, T. B.;Woodward, S. C.
  7. J. Cell. Physiol. v.152 Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro Downs, E. C.;Robertson, N. E.;Riss, T. L.;Plunkett, M. L.
  8. N. Engl. J. Med. v.321 Enhancement of wound healing by topical treatment with epidermal growth factor Brown, G. L.;Nanney, L. B.;Griffen, J.;Cramer, A. B.;Yancey, J. M.;Curtsinger, L. J.;Holtzin, L.;Schultz, G. S.;Jurkiewicz, M. J.;Lynch, J. B.
  9. Am. J. Surgery v.167 Donor site repair Smith Jr., D. J.;Thomson, P. D.;Garner, W. L.;Rodriguez, J. L.
  10. J. Pharm. Pharmacol. v.46 Effect of Epidermal growth factor dosage forms on dermal wound strength in mice Celebi, N.;Erden, N.;Gonul, B.;Koz, M.
  11. Pharm. Res. v.7 Improvement in wound healing by EGF ointment Ⅰ. Effect of nafamostat, gabexate or gelatin on stabilization and efficacy of EGF. Okumura, K.;Kiyohara, Y.;Komada, F.;Iwakawa, S.;Hirai, M.;Fuwa, T.
  12. J. Pharmacobio-Dyn v.14 Improvement in wound healing by EGF ointment Ⅱ.Effect of protease inhibitor, nafamostat on stabilization and efficacy of EGF in burn Kiyohara, Y.;Komada, F.;Iwakawa, S.;Hirai, M.;Fuwa, T.;Okumura, K.
  13. Biol. Pharm. Bull. v.16 Systemic effects of EGF ointment containing protease inhibitor or gelatin in rats with burns or open wounds Kiyohara, Y.;Komada, F.;Iwakawa. S.;Fuwa, T.;Okumura, K.
  14. Biol. Pharm. Bull. v.16 Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats Kiyohara, Y.;Nishiguchi, K.;Komada, F.;Iwakawa, S.;Hirai, M.;Okumura, K.
  15. Yakuzaigaku v.54 Improvement in wound healing by epidermal growth factor ointment Kiyohara, Y.;Komada, F.;Iwakawa, S.;Okumura, K.
  16. J. Pharm. Sci. v.82 Effect of absorption promoters on subcutaneous absorption of hEGF in rats Murakami, T.;Misaki, M.;Kojima, Y.;Yamada, M.;Yuki, M.;Higashi, Y.;Amagase, H.;Fuwa, J.;Yata, N.
  17. Int. J. Pharm. v.46 Intravenous and subcutaneous pharmacokinetics and rectal bioavailability of human epidermal growth factor in the presence of absorption promoter in the rats Murakami, T.;Kawakita, H.;Kishimoto, M.;Higashi, Y.;Amagase, H.;Hayashi, T.;Nojima, N.;Fuwa, T.;Yata, N.
  18. Drug Dis. Sci. v.39 Systemic treatment with recombinant human epidermal growth factor accelarates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs Juhl, C. O.;Vinter-Jensen, L.;Jensen, L. S.;Nexo, E.;Djurhuus, J. C.;Dajani, E. Z.
  19. J. Endocrinol v.144 Tissue distribution of $^{131}I$-labelled epidermal growth factor in the pig visualized by dynamic scintigraphy Vinter-Jensen, L.;Frokiaer, J.;Jorgensen, P. E.;Marqversen, J.;Rehling, M.;Dajani, E. Z.;Nexo, E.
  20. J. Pharmacobio-Dyn v.11 Radioimmunoassay of human epidermal growth factor-hEGF levels in human body fluids Hayashi, T.;Sakamoto, S.
  21. Percutaneous absorption drug Determination of percutaneous absorption by in vitro techniques Bronaugh, R. L.
  22. Ph. D. Thesis, University of Rhode Island Topical of formulation of epidermal growth factor wound healing Dibiase, M. D. G.
  23. J. Endocrinol v.123 The fate and uptake of murine epidermal growth factor in the sheep Tyson, L. M.;Browne, C. A.;Jenkin, G.;Thorburn, G. D.
  24. J. Endocrinol v.121 Characterization and localization of receptors for epidermal growth factor in ovine skin Wynn, P. C.;Maddocks, I. G.;Moore, G. P. M.;Panaretto, B. A.;Djura, P.;Ward, W. G;Fleck, E.;Chapman, R. E.
  25. Chem. Pharm. Bull. v.35 Binding of human epidermal growth factor to tissue homogenates of the rat Yanai, S.;Sugiyama, Y.;Kim, D. C.;Sato, H.;Fuwa, T.;Iga, T.;Hanano, M.
  26. J. Gastroenterol v.83 Characterization of epidermal growth factor binding to hepatic plasma membranes of rainbow trout Newsted, J. L.;Giesy, J. P.
  27. Anal. Biochem. v.110 A rapid fluorometric method for the estimation of DNA in cultured cells Erwin, B.;Stoscheck, C. M.;Florini, J. R.
  28. Pharm. Acta Helv v.70 Dermal metabolism of topically applied drugs. Pathways and models reconsidered Steinstrasser, I.;Merkle, H. P.
  29. Pharm. Res. v.10 Physiological parameters in laboratory animals and humans Davies, B.;Morris, T.
  30. J. Control. Rel. v.26 Transdermal iontophoresis of sotalol and salicylate, the effect of skin charge and penetration enhancers Hirvonen, J.;Kontturi, K.;Murtomaki, L.;Paronen, P.;Urtti, A.
  31. Human physiology Movement of molecules across cell membranes Vander, A. J.;Sherman, J. H.;Luciano, D. S.
  32. J. Cell. Physiol. v.157 Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities Liu, S. M.;Carpenter, G.
  33. J. Invest. Dermatol. v.99 Quantitative determination of EGF-R during epidermal wound healing Stoscheck, C. M.;Nanney, L. B.;King, Jr., L. E.
  34. J. Invest. Dermatol v.86 Altered [$^{125}I$]epidermal growth factor binding and receptor distribution in psoriasis Nanney, L. B.;Stoscheck, C. M.;Magid, M.;King. Jr., L. E.
  35. Int. J. Pharm. v.62 Comparison of enzymic activities of tissues lining portals of drug absorption, using the rat as a model Zhou, X. H.;Li Wan Po, A.
  36. J. Fac. Pharm. Gazi. v.11 Increases in acid proteinase and breaking strength during wound healing Kilic, N.;Gonul, B.;Aldemir, H.;Koz, M.
  37. Chem. Pharm. Bull. v.37 Stability of rhEGF in various solutions Araki, F.;Nakamura, H.;Nojima, N.;Tsukumo, K.;Sakamoto, S.
  38. J. Clin. Invest. v.90 Epidermal growth factor receptor distribution in burn wounds Wenczak, B. A.;Lynch, J. B.;Nanney, L. B.